Anisotropy characterization of I-125 seed with attached encapsulated cobalt chloride complex contrast agent markers for MRI-based prostate brachytherapy

Medical Dosimetry

Volumn 36, Issue 2, 2011, Pages 200-205

  Frank, Steven J ^a   Tailor, Ramesh C ^a   Kudchadker, Rajat J ^a   Martirosyan, Karen S ^b   Stafford, R Jason ^a   Elliott, Andrew M ^a   Swanson, David A ^a   Sing, David ^a   Choi, Jonathan ^a   Mourtada, Firas ^a   Ibbott, Geoffrey S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

Fiducial marker; MRI based dosimetry; Post implant dosimetry; Prostate brachytherapy

Indexed keywords

COBALT CHLORIDE COMPLEX CONTRAST AGENT ENCAPSULATED CONTRAST AGENT MARKER; CONTRAST MEDIUM; IODINE 125; UNCLASSIFIED DRUG;

ANISOTROPY; ARTICLE; BRACHYTHERAPY; CONTROLLED STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHANTOM; PRIORITY JOURNAL; PROSTATE; RADIATION EXPOSURE; THERMOLUMINESCENCE DOSIMETER;

ANISOTROPY; BRACHYTHERAPY; COBALT; CONTRAST MEDIA; HUMANS; IMAGE ENHANCEMENT; IODINE RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; MALE; PHANTOMS, IMAGING; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 79955476904     PISSN: 09583947     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.meddos.2010.03.004     Document Type: Article

References (13)

1. NCCN Clinical Practice Guidelines in Oncology. Home page Accessed September 1, 2009. http://www.nccn.org.
2. Merrick G.S., Butler W.M., Wallner K.E., et al. Variability of prostate brachytherapy pre-implant dosimetry: A multi-institutional analysis. Brachytherapy. 2005, 4:241-251.
3. McLaughlin P.W., Troyer S., Berri S., et al. Functional anatomy of the prostate: Implications for treatment planning. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63:479-491.
4. Nag S., Bice W., DeWyngaert K., et al. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int. J. Radiat. Oncol. Biol. Phys. 2000, 46:221-230.
5. Frank S.J., Stafford R.J., Bankson J.A., et al. A novel MRI marker for prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 2008, 71:5-8.
6. Martirosyan K.S., Stafford R.J., Elliott A.M., et al. PMMA/SWCNTs composites for prostate brachytherapy MRI contrast agent markers. NSTI-NanoTech. 2009, 2:44-47.
7. Rivard M.J., Coursey B.M., DeWerd L.A., et al. Update of AAPM Task Group No. 43 report: A revised AAPM protocol for brachytherapy dose calculations. Med. Phys. 2004, 31:633-674.
8. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med. Phys. 1995, 22:209-234.
9. Tailor R., Tolani N., Ibbott G.S. Thermoluminescence dosimetry measurements of brachytherapy sources in liquid water. Med. Phys. 2008, 35:4063-4069.
10. Servois V., Chauveinc L., El Khoury C., et al. [CT and MR image fusion using two different methods after prostate brachytherapy: Impact on postimplantation dosimetric assessment]. Cancer. Radiother. 2003, 7:9-16. [French].
11. Amdur R.J., Gladstone D., Leopold K.A., et al. Prostate seed implant quality assessment using MR and CT image fusion. Int. J. Radiat. Oncol. Biol. Phys. 1999, 43:67-72.
12. Bloch B.N., Lenkinski R.E., Helbich T.H., et al. Prostate postbrachytherapy seed distribution: Comparison of high-resolution, contrast-enhanced, T1- and T2-weighted endorectal magnetic resonance imaging versus computed tomography: Initial experience. Int. J. Radiat. Oncol. Biol. Phys. 2007, 69:70-78.
13. D'Amico A.V., Cormack R., Tempany C.M., et al. Real-time magnetic resonance imaging-guided interstitial brachytherapy in the treatment of select patients with clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 1998, 42:507-515.